Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Cancer J. 2012 Mar;18(2):124–131. doi: 10.1097/PPO.0b013e31824b436e

Figure 2.

Figure 2

Targeted kinase inhibitors of the MAPK and PI3K/AKT/mTOR pathways. Several compounds such as AZ628, dabrafenib, GDC-0879, SB90885 and XL281 are being evaluated for clinical use with vemurafenib being the only currently FDA approved BRAF inhibitor. Compounds that target the MAPK cascade such as the MEK inhibitor GSK1120212 and the ERK inhibitor SCH772984 as well as PI3K, AKT and mTOR inhibitors are also being developed as single and combined agents for the treatment of BRAF mutant melanomas.